Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT02557100
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Abatacept — DRUG
- Adalimumab — DRUG
- Methotrexate — DRUG
Study Details
The purpose of this study is to examine changes in immune cells and proteins in response to treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus adalimumab, both given in combination with methotrexate.
Key Dates
- Start date
- Nov 19, 2015
- Status verified
- Aug 2020
- Primary completion
- Mar 28, 2019
- Completion
- Mar 28, 2019
Study Design
- Enrollment
- 80 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Treatment AAbatacept Single Blind Treatment Period
- Active Comparator: Treatment BAdalimumab Single Blind Treatment Period
- Active Comparator: Treatment CAbatacept Cumulative Treatment Period
Primary Outcome Measure
Percentage of Adverse Events (AEs) [ Time Frame: up to 85 days post last dose, approximately 40 weeks ]
Locations (21)
Find similar trials in Birmingham, AL
By condition
By research site
University Of Alabama At Birmingham· Birmingham, ALRheumatology Associates Of North Alabama, P.C.· Huntsville, ALClinical And Translational Research Center Of Alabama, Pc· Tuscaloosa, ALArizona Arthritis & Rheumatology Research PLLC· Glendale, AZArizona Arthritis & Rheumatology Research PLLC· Phoenix, AZSt. Joseph Heritage Medical Group· Fullerton, CA
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Rheumatoid Arthritis Patients at Risk for Interstitial Lung DiseaseRecruiting · University of Colorado, Denver · Aurora, Colorado
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama